Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24834446 | 0.84 | GRIA2 (0.51) | FDPSTBXAS1FPR2TAAR1GRIA1 | |
| SCHEMBL781663 | 0.84 | GRIA2 (0.51) | FDPSTBXAS1FPR2TAAR1GRIA1 | |
| SCHEMBL10838551 | 0.84 | TBXAS1 (0.42) | FDPSTBXAS1FPR2TAAR1HTR1A | |
| SCHEMBL3838965 | 0.84 | GRIA2 (0.51) | FDPSTBXAS1FPR2TAAR1GRIA1 | |
| Hydrochloric Acid SCHEMBL10837657 | 0.83 | TBXAS1 (0.44) | FDPSTBXAS1FPR2TAAR1HTR1A | |
| SCHEMBL10836428 | 0.82 | FPR2 (0.39) | FDPSTBXAS1FPR2TAAR1HTR1A | |
| SCHEMBL16481708 | 0.82 | FPR2 (0.39) | FDPSTBXAS1FPR2TAAR1HTR1A | |
| SCHEMBL10837738 | 0.82 | FPR2 (0.42) | FDPSTBXAS1FPR2TAAR1HTR1A | |
| SCHEMBL10838983 | 0.82 | FPR2 (0.39) | FDPSTBXAS1FPR2TAAR1HTR1A | |
| Hydrochloric Acid SCHEMBL11090438 | 0.81 | GRIA1 (0.49) | FDPSTBXAS1FPR2TAAR1GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2559434-A2 | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist | Nicolaou, Mike (US) | 2013-02-20 | — | — | EP | claimed |
| US-20120295933-A1 | TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBATORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS | LORIA EMILE (US) | 2012-11-22 | — | — | US | claimed |
| US-20100144718-A1 | TREATMENT OF DISEASES MODULATED BY A H4 RECEPTOR AGONIST | NICOLAOU MICHALIS | 2010-06-10 | — | — | US | claimed |
| EP-2170317-A1 | TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBITORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS | Nicolaou, Mike (US) | 2010-04-07 | — | — | EP | claimed |
| US-20080207530-A1 | Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs | NICOLAOU MICHALIS | 2008-08-28 | — | — | US | claimed |
| WO-2008100539-A1 | TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBITORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS | NICOLAOU MICHALIS (US) | 2008-08-21 | — | — | WO | claimed |
| US-20130059878-A1 | TREATMENT OF DISEASES MODULATED BY A H4 RECEPTOR AGONIST | LORIA EMILE (US) | 2013-03-07 | — | — | US | disclosed |
| EP-2559434-A2 | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist | Nicolaou, Mike (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20120295933-A1 | TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBATORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS | LORIA EMILE (US) | 2012-11-22 | — | — | US | disclosed |
| US-8207292-B2 | Tritoqualine or isomer, alpha-fluoromethylhistidine, 3-methoxy-5,7,3',4'-tetrahydroxyflavan, naringenin, cyanidanol-3, His-Phe dipeptide, 4-imidazolyl-3-amino-2-butanone, epigallocatechin gallate and other catechins; | NICOLAOU MICHALIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207188-B2 | Treatment of diseases modulated by a H4 receptor agonist | NICOLAOU MICHALIS (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100144718-A1 | TREATMENT OF DISEASES MODULATED BY A H4 RECEPTOR AGONIST | NICOLAOU MICHALIS | 2010-06-10 | — | — | US | disclosed |
| EP-2170317-A1 | TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBITORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS | Nicolaou, Mike (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20080207530-A1 | Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs | NICOLAOU MICHALIS | 2008-08-28 | — | — | US | disclosed |
| WO-2008100539-A1 | TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBITORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS | NICOLAOU MICHALIS (US) | 2008-08-21 | — | — | WO | disclosed |